secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0000950170-24-031478
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio reports Q4 2023 net loss of $7.6M and cash of $21.3M; highlights positive clinical data
--------------------------------------------------------------------------------

- Q4 2023 net loss $7.6M ($0.22 per share) vs Q4 2022 net loss $7.8M ($0.32 per share).
- Full-year 2023 net loss $30.0M ($1.00 per share); R&D expenses increased to $16.8M.
- Cash $21.3M as of Dec 31, 2023 vs $18.2M a year earlier; private placement extended runway into 1Q 2025.
- 100% of evaluable leukemia patients (n=10) in INB-100 Phase 1 remained in remission as of Nov 3, 2023.
- Appointed Dr. Corinne Epperly, M.D., M.P.H. to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000095017024031478/0000950170-24-031478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000095017024031478/inab-20240314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-031478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer